Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of TRC041266 Compared to Placebo in Patients With Chronic Stable Heart Failure, an LVEF ≥40%, Moderate to Severe Diastolic Dysfunction and Type 2 Diabetes Mellitus
Latest Information Update: 29 Dec 2022
At a glance
- Drugs TRC 041266 (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Torrent Pharmaceuticals
- 23 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Aug 2020 New trial record